A2M Therapy

Alpha-2-macroglobulin (A2M) is a powerful inhibitor of cartilage catabolic factors and stops the progression of Osteoarthritis (OA) by preventing cartilage breakdown and preventing cartilage loss.

Cytonics has developed a breakthrough molecular technology that concentrates the alpha-2-macroglobulin (A2M) in your blood to deliver high concentrations in your joint space, protecting your joint space from the destructive proteins that cause Osteoarthritis (OA).

Osteoarthritis (OA) is one of the most common health problems we face today.

With nearly 30 Million Americans suffering from OA, the US Medical Expenses exceed $185.5 Billion dollars spent annually on treating conditions associated with Osteoarthritis, including knee pain, back pain, Post Traumatic OA, and many other joint conditions. Though current non-surgical Osteoarthritis (OA) treatment options show potential to offer temporary symptomatic relief, they have side effects and are ineffective at treating the root cause of OA.

Arthritic joints make several chemicals that destroy the cartilage, which is the essence of osteoarthritis. These chemicals, called catabolic proteases, work by degrading cartilage and damaging your joint by breaking down the cells.

Alpha-2-macroglobulin (A2M), found naturally in the blood, binds (captures) these “bad” chemicals produced in the knee andneutralizes their degenerative effect.

Injections of concentrated A2M is the first treatment for OA that can inhibit all causes of cartilage breakdown and thereby prevent cartilage loss, reduce pain, and stop the progression of OA.

A short breakdown of A2M Therapy

Alpha-2-Macroglobulin (A2M) Rich – 6 times the concentration found in blood